MKM Partners analyst Rohit Kulkarni maintains Yext (NYSE:YEXT) with a Neutral and lowers the price target from $8 to $6.
Kineta Publishes Preclinical Data Demonstrating The Potential Of Anti-VISTA Antibody KVA12123 As An Immunomodulatory Therapy For Cancer
VISTA Blocking KVA12123 Monoclonal Antibody (mAb) Engineered to Provide Strong Single Agent Anti-Tumor Activity While Minimizing Cytokine Related Adverse EventsKVA12123 recognizes a unique VISTA epitope and binds at
